So far, several interfering peptides targeting transcription factors have been validated for cancer treatment in preclinical studies (e.g., TCF4 N-terminus-derived peptide targeting β-catenin:TCF interaction [5], p73 DBD-derived peptide targeting p53:p73 interaction [6], and GAPDH-derived peptide targeting p53:GAPDH interaction [7]) or in clinical trials (e.g., NSC745104 targeting p53:HDM2 interaction [8] and Omo-103 targeting C-Myc:Max interaction [9]). This evidence concerns the gene TP53 and cancer.